Skip to main content
    A

    Arcadia Biosciences Inc (RKDA)

    Official site

    CONSUMER DEFENSIVE • PACKAGED FOODS • NASDAQ

    $0.19
    -0.02 (-11.19%)

    Market Cap: $1.32M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Arcadia Biosciences Inc (RKDA) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Arcadia Biosciences (RKDA) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, Arcadia Biosciences reported EPS of $0.29. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    51%(19/37)
    Avg Surprise
    -24.60%

    Next Report

    RKDA has an expected report date of Mar 24, 2027.

    RKDA Earnings Call

    The latest RKDA earnings call transcript on file is labeled 2025Q1.

    Read the 2025Q1 transcript

    Earnings History

    Of the 37 quarters below that had an estimate, RKDA beat 19 and missed 18. Revenue for the quarter ended Sep 30, 2026 was $1.62M, up 24.6% from $1.30M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.29N/AN/AN/AN/A-53.2%N/AN/ANov 12, 2026$1.62M
    Jun 30, 2026-$0.38N/AN/AN/AN/AN/AN/AN/AAug 13, 2026$1.44M
    Mar 31, 2026-$2.11-$0.80-$0.80 - -$0.80N/AN/A-210.8%10 up, 0 downMay 14, 2026$1.10M
    Dec 31, 2025-$0.98-$0.09N/A-984.33%MissN/AN/AN/AMar 26, 2026$901000
    Sep 30, 2025$0.62-$0.54-$0.54 - -$0.54+214.81%BeatN/A10 up, 1 downNov 7, 2025$1.30M
    Jun 30, 2025-$3.26-$0.79N/A-312.66%Miss-517.9%N/A0 up, 0 downAug 14, 2025$1.46M
    Mar 31, 2025$1.90-$0.98N/A+293.88%BeatN/AN/A0 up, 0 downMay 8, 2025$1.20M
    Dec 31, 2024-$2.99-$0.89N/A-235.96%MissN/AN/A0 up, 0 downMar 20, 2025$1.22M
    Sep 30, 2024-$0.87-$0.77-$0.85 - -$0.77-12.99%MissN/A20 up, 0 downNov 12, 2024$1.54M
    Jun 30, 2024$0.78$1.55$1.27 - $1.83-49.68%Miss+27.9%20 up, 0 downAug 13, 2024$1.31M
    Mar 31, 2024-$1.78-$2.21-$2.52 - -$1.91+19.46%BeatN/A21 up, 0 downMay 9, 2024$987000
    Dec 31, 2023-$2.52-$2.58-$2.68 - -$2.49+2.33%BeatN/A20 up, 0 downMar 28, 2024$627000
    Sep 30, 2023-$1.89-$2.93N/A+35.49%BeatN/A10 up, 0 downNov 9, 2023$1.30M
    Jun 30, 2023$0.61-$4.92N/A+112.40%BeatN/A20 up, 0 downAug 10, 2023$1.30M
    Mar 31, 2023-$10.86-$6.60N/A-64.55%MissN/A11 up, 0 downMay 11, 2023$1.23M
    Dec 31, 2022-$6.29-$6.80-$6.80 - -$6.80+7.50%BeatN/A10 up, 0 downMar 30, 2023N/A
    Sep 30, 2022-$7.70-$7.60-$9.20 - -$7.60-1.32%MissN/A20 up, 0 downNov 10, 2022$1.57M
    Jun 30, 2022-$8.28-$12.40N/A+33.23%BeatN/AN/A0 up, 0 downAug 11, 2022$3.86M
    Mar 31, 2022-$8.74-$12.40-$14.80 - -$12.40+29.52%BeatN/A20 up, 0 downMay 12, 2022$3.22M
    Dec 31, 2021-$11.20-$12.00-$12.80 - -$11.20+6.67%Beat-131.8%20 up, 0 downMar 30, 2022$2.17M
    Sep 30, 2021-$12.35-$9.60-$14.40 - -$9.20-28.65%MissN/A30 up, 1 downNov 15, 2021$2.38M
    Jun 30, 2021-$8.76-$9.20-$14.40 - -$9.20+4.78%BeatN/A3N/AAug 16, 2021$1.41M
    Mar 31, 2021-$11.86-$12.20-$15.60 - -$8.80+2.79%BeatN/A2N/AMay 17, 2021$828000
    Dec 31, 2020$35.20-$16.40-$17.60 - -$15.20+314.63%BeatN/A2N/AMar 30, 2021$7.13M
    Sep 30, 2020-$25.52-$21.60-$22.40 - -$20.80-18.15%MissN/A3N/ANov 12, 2020$314000
    Jun 30, 2020-$28.56-$24.20-$28.00 - -$20.40-18.02%MissN/A3N/AAug 13, 2020$281000
    Mar 31, 2020-$25.80-$19.20-$24.40 - -$19.20-34.38%MissN/A2N/AMay 13, 2020$309000
    Dec 31, 2019-$20.00-$23.00-$24.40 - -$21.60+13.04%BeatN/A2N/AMar 25, 2020$416000
    Sep 30, 2019-$36.93-$31.20-$32.80 - -$28.40-18.37%MissN/A3N/ANov 6, 2019$392000
    Jun 30, 2019-$41.50-$37.60N/A-10.37%MissN/A2N/AAug 14, 2019$203000
    Mar 31, 2019-$34.48-$40.40-$40.40 - -$24.40+14.65%BeatN/A2N/AMay 8, 2019$158000
    Dec 31, 2018-$5.60-$30.40-$30.40 - -$30.40+81.58%BeatN/A1N/AMar 27, 2019$444000
    Sep 30, 2018-$33.26-$45.20-$45.20 - -$45.20+26.42%BeatN/A1N/ANov 7, 2018$370000
    Jun 30, 2018-$80.80-$51.60N/A-56.59%MissN/AN/AN/AAug 8, 2018$436000
    Mar 31, 2018-$194.40-$56.00N/A-247.14%MissN/AN/AN/AMay 9, 2018$214000
    Dec 31, 2017-$1.39-$2.00N/A+30.50%BeatN/AN/AN/AMar 20, 2018$1.43M
    Sep 30, 2017-$67.92-$64.00N/A-6.13%MissN/AN/AN/ANov 9, 2017$589000
    Jun 30, 2017-$72.00-$88.00N/A+18.18%BeatN/AN/AN/AAug 10, 2017$991000
    Mar 31, 2017-$80.00-$56.00N/A-42.86%MissN/AN/AN/AMay 10, 2017$1.02M
    Dec 31, 2016-$104.00-$80.00N/A-30.00%MissN/AN/AN/AMar 8, 2017$540000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.72, after -$4.86 the year before. It was -$352.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.72N/A
    Dec 31, 2024-$4.86N/A
    Dec 31, 2023-$14.66N/A
    Dec 31, 2022-$31.01N/A
    Dec 31, 2021-$44.17N/A
    Dec 31, 2020-$44.68N/A
    Dec 31, 2019-$132.91N/A
    Dec 31, 2018-$314.06N/A
    Dec 31, 2017-$221.31N/A
    Dec 31, 2016-$352.00N/A

    Earnings Calls

    The 4 most recent earnings calls are listed below; the latest, 2025Q1 for the period ended Mar 31, 2025, runs about 3,200 words across 4 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q1Mar 31, 20253,2024
    2024Q4Dec 31, 20242,5344
    2024Q3Sep 30, 20241,8974
    2024Q2Jun 30, 20243,3975

    2025Q1 Earnings Call

    Opening remarks

    Mark Kawakami CFO Thank you. Joining me on the call today is T.J. Schaefer, Arcadia's President and Chief Executive Officer. This call is being webcast, and you can refer to the company's press release at ArcadiaBio.com. Before we start, I would like to remind you that Arcadia Biosciences, Inc. will be making forward-looking statements on this call based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied today. You can review the company's safe harbor language in our most recently filed 10-K. With that, I will now turn the call over to T.J. Schaefer.

    T.J. Schaefer President & CEO Thanks, Mark, and thank you to everyone on the call for joining us today to discuss our 2025 first quarter financial results. It has only been seven weeks since we delivered our 2024 year-end update, but the momentum from the second half of 2024 has carried into 2025, and I am very pleased with our first quarter results. Zola coconut water continues to thrive and outperform our own internal expectations. In Q1 2025, our revenue grew 90% year-over-year, primarily driven by new distribution gains, which increased 70% compared to the same period last year. We continue to implement tight cost controls, resulting in strong gross margins and a 16% year-over-year reduction in operating expenses, inclusive of nearly half a million dollars in transaction-related fees during the quarter. In addition to our strong brand performance, we also made significant progress during the quarter monetizing our intellectual property, a goal we have discussed for several years. Finally, the pending business combination with Roosevelt Resources continues to move forward, and we believe it is on track to be completed towards the end of the summer. Today, I would like to discuss each of these topics in more detail, starting with the performance of Zola. As I just mentioned, our revenue from Zola increased 90% compared to the same quarter last year, primarily driven by a 70% increase in new distribution. Growing Zola's presence in the marketplace has been a focus of Arcadia Biosciences, Inc., and we believe it represents our best opportunity to significantly increase our share of coconut water industry sales, given our relatively low penetration rate. Our sell-through or scan data sales increased 76% during the 13 weeks ended March 29, 2025, based on Nielsen data. This rate of sales growth is more than three times faster than the coconut water category, which grew 24% during the same time period. Coconut water continues to outpace the growth of many other beverage categories, driven by the shift in consumer preferences toward healthy, better-for-you beverages.

    Frequently Asked Questions About RKDA

    When is Arcadia Biosciences's next earnings date?

    Arcadia Biosciences's next earnings report is expected for Mar 24, 2027.

    How often does RKDA beat earnings estimates?

    Arcadia Biosciences beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -133.43%.